Bioventures Investors LLC

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

145 documents for Bioventures Investors LLC

- Akebia Draws Down $4.1 Million Series B Financing Tranche.
...Investors included Novartis Bioventures, Venture Investors L...
- Business Wire
- January 09, 2012
- RainDance Technologies Raises $37.5 Million in Series D Financing.
... was co-led by new investor Quaker BioVentures and existing investor Mohr Davidow Ventures. Existting investors Alloy Ventures and Acadia Woods, LLC also particip...
- Business Wire
- January 25, 2011
- HydroCision, Inc. Elects Peter Feinstein and Art Rosenthal to Board of Directors.
..., Managing Director and founder of BioVentures Investors LLC, a venture fund investing in the hea...
- Business Wire
- February 12, 2008

- Businessnotes
NovaSom Inc. of Glen Burnie has raised $35 million to expand its business. The company offers a diagnostic device and online patient management systems for physicians, therapists and insurance companies offering treatment for obstructive sleep apnea. The company raised the funds from existing investors including TPG Biotechnology II Fund and Quaker BioVentures. ***
- Maryland Gazette
- June 29, 2011
- Interventional Spine, Inc. Completes $24 Million Financing.
...Other investors were Wexford Capital LLC, HBM BioVentures, Rock Cr...
- Business Wire
- May 31, 2007
- BioPartnering North AmericaTM Kicks Off with Record Attendance and an Upbeat Outlook for 2011.
... attracting attention from pharma and investors in the audience. Because of the success and signif... into BioPartnering India(TM) and C21 BioVentures(TM) taking place in May 2011. TVG's presenter sele...
- Business Wire
- February 28, 2011
- Michigan Growth Capital Symposium Reveals Programming and Final Call for Presenting Companies for 30th Annual Event
Life Sciences Investment Trends, Early Stage Investments, and Venture Capital Regulation among Topics to Be Discussed By High Profile Investors from Across the Nation ANN ARBOR, Mich., March 9, 2011 /PRNewswire-USNewswire/ -- The Michigan Growth Capital Symposium, which is hosted by the Ross School of Business' Zell Lurie Institute at the University of Michigan with support from the Michigan Venture Capital Association, today unveiled details on the topics and experts that will be a part of this year's robust event programming. As part of its legacy of shining a spotlight on the extraordinary innovation and investment opportunities in the Midwest, the symposium will feature five panel discussions, two days of continuous networking opportunities and presentations from 44 of the region's ...

... Spine, Versant Ventures, and BioVentures. Navigating Regulatory Policies in Venture Capital...
- U.S. Newswire
- March 09, 2011
- Safeguard Scientifics Participates in Follow-On Series C Equity Financing for Tengion, Inc.
... from Tengion's current institutional investors, including Bain Capital LLC, Johnson & Johnson Dev..., Deerfield Partners, Quaker BioVentures, Oak Investment Partners, HealthCap and L Capital ...
- Business Wire
- November 19, 2008
- A stronger economy and deal diversity driving private equity and venture capital growth.
... companies funded by private equity investors last year, most of the private equity investors he...; Versant Ventures; Abingworth Bioventures V, L.P. 04/21/2011 Medsurant Volante Capital, LLC ...
- ColoradoBiz
- Vol. 39 Nbr. 2, February 2012
- The Daily Record Business Briefs: June 27, 2011
Big bucks for NovaSom NovaSom Inc. of Glen Burnie, a company providing home diagnosis and treatment of sleep-related breathing disorders such as obstructive sleep apnea, said it closed on $35 million in equity financing. The Series D financing round was led by Pennsylvania- based Safeguard Scientifics Inc., which provided $20 million. Also participating were existing investors TPG Biotechnology II Fund of San Francisco and Philadelphia-based Quaker BioVentures, among others. NovaSom will use the financing to fund growth, expand its position in payer and provider markets, and develop additional innovations within the company's proprietary NovaSom diagnostic medical device and cloud-based MediTrack Patient Management portals.
- The Daily Record (Baltimore)
- July 04, 2011